Dr. John Cush RheumNow
1 year 5 months ago
EMA has approved upadacitinib (Rinvoq) for use in the EU to treat adult patients with giant cell arteritis (GCA) - approval is based on data from the Phase 3 SELECT-GCA trial demonstrating sustained remission and key secondary endpoints https://t.co/Y2tyZPC9Et https://t.co/SHPz2Q94Vs
Dr. John Cush RheumNow
1 year 5 months ago
JAMA Staphylococcus aureus Review
- s. aureus bacteremia leads to septic arthritis (7%), vertebral osteomyelitis (≈4%)
- bacteremia (≥48 hs) has 39% 90-day mortality risk
https://t.co/1UQoz7JDPU https://t.co/xTAkakv2he
Dr. John Cush RheumNow
1 year 5 months ago
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/fw8wcuS48E https://t.co/LgS3Sxy7gd
Dr. John Cush RheumNow
1 year 5 months ago
EPIC EHR data assessed pre- & post-COVID. Pt messaging increased w/ pandemic & remained elevated, w/ no change in pt phone calls. MD EHR time/wk increased for all MDs, post COVID-19: (PCP +6.5%), subspecialists (+9.9%), surgeons (+5.2%). https://t.co/j8zwPkdmp9 https://t.co/SyYpZwnMfN
A CDC cross-sectional national study showed an increase in pregnancy-related deaths in the US from 2018 to 2022, with highest rates among American Indian, Alaska Native women, and non-Hispanic Black women.
A randomized clinical trial in knee osteoarthritis (KOA) patients showed both yoga and strengthening improved knee pain over 12 weeks, with no difference between groups.There is limited evidence on the comparative effectiveness of yoga and strengthening exercises in managing knee osteoarthritis (OA).
Dr. John Cush RheumNow
1 year 5 months ago
Korean insurance claims study (2008–2021) 183,212 psoriasis & PsA pts, found Biologic Rx assoc w/ lower risk of new-onset & recurrent MACEs vs phototherapy (adj HR, 0.45 & 0.34). Nonbiologic systemic Rx lowered MACE risk (v photoRx) only in pts w/ prior Hx MACE (0.79) https://t.co/08wNm1AbpC
Dr. John Cush RheumNow
1 year 5 months ago
2nd Opinions in Rheumatology
https://t.co/KqXFBJPOAQ https://t.co/QGXxkXVp3T
Dr. John Cush RheumNow
1 year 5 months ago
Does DMARD Rx affect neurocognitive function in older pts? bDMARDs targeting TNF-α & IL-6 may mitigate neuroinflammation & preserve cognitive function. But, cognitive impact of csDMARDs (MTX) is complex, w/ conflicting reports on its role in vascular dementia. https://t.co/6uMmOOdRoF
Dr. John Cush RheumNow
1 year 5 months ago
Mindfulness and CBT improve chronic low back pain
Behavioral interventions were associated with reduced pain and daily opioid use and improved function and quality of life for up to 12 months among adults with opioid-treated chronic low back pain, according to a new randomized https://t.co/e4jLNwNBy3
Dr. John Cush RheumNow
1 year 6 months ago
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/tnYgg6MNXp https://t.co/zJor1oTFfD
Dr. John Cush RheumNow
1 year 6 months ago
EMA has approved upadacitinib (Rinvoq) for use in the EU to treat adult patients with giant cell arteritis (GCA) - approval is based on data from the Phase 3 SELECT-GCA trial demonstrating sustained remission and key secondary endpoints https://t.co/ycPNuB8C8y https://t.co/MCJNltn8Lj
Dr. John Cush RheumNow
1 year 6 months ago
An Epidural Letdown (4.4.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv.
https://t.co/YDxQWukJ5U https://t.co/Pr7tG5rU0R
Dr. John Cush RheumNow
1 year 6 months ago
Danish registry study of 1431 AAV pts ((median age: 69 yrs, 52M; F/U 4.8 yrs) shows AAV had more LVH (17% vs 12%), ST-T (10% vs 7%), aFib (9.6% vs 7.5%), QTc prolong (6% vs 3.6%). Only AAV w/ major ECG abnls had incr risk of CV mortality [HR 1.99; 1.49-2.65) https://t.co/OB8b9pC6kw
Researchers at the University of Colorado have identified pathogenic immune phenotypes in at-risk populations for rheumatoid arthritis (RA). They have found the expansion of specific T cell subtypes, in the at-risk group, and postulate this could lead to future immunospecific prevention strategies.
